Australia’s Gold Coast truly represents one of the most beautiful places in the world. Its Griffith University Institute for Glycomics received $500,000 from the government earlier this year to support their ongoing clinical trials program aiming to test the effectiveness of a world-first malaria vaccine candidate called PlasProtecT.™
Malaria is a Killer
Malaria, caused by an infection with malaria parasites threatens over 3 billion living in malaria-endemic countries worldwide. At least 500,000 die annually—children represent 80% of the casualties.
What is PlasProtecT™?
PlasProtecT was developed and is owned by Griffith University Institute for Glycomics. It is a chemically attenuated, whole parasite, blood-stage malaria vaccine candidate. Demonstrating the ability to elicit cross-strain and cross-species protective immune response in rodent models, it has evidenced immunogenic results in first-in-man clinical trials.
Institute for Glycomics
The Institute for Glycomics was founded nearly two decades ago at Griffith University. Embracing multidisciplinary research centers around glycomics makes Griffith a one of its kind in Australia and one of a handful worldwide.
Dr. Chris Davis, General Manager
Call to Action: Interested in learning more about PlasProtecT? See www.griffith.edu.au/institute-glycomics/malaria-vaccine-trial